EntryPoint Capital LLC Acquires Shares of 9,675 Mirum Pharmaceuticals, Inc. $MIRM

Key Points

• EntryPoint Capital LLC invested $436,000 in Mirum Pharmaceuticals, acquiring 9,675 shares, as reported in their recent SEC filing.
• Multiple hedge funds have increased their stakes in Mirum Pharmaceuticals, with notable increases from Vanguard Group Inc. (4.8%) and Nuveen Asset Management LLC (46.7%) in the last quarter.
• Mirum Pharmaceuticals received a consensus rating of "Buy" from analysts, with an average target price of $74.13 and recent upgrades from multiple research firms.

EntryPoint Capital LLC purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,675 shares of the company's stock, valued at approximately $436,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $35,000. GF Fund Management CO. LTD. acquired a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $42,000. KBC Group NV acquired a new position in Mirum Pharmaceuticals during the first quarter valued at approximately $89,000. Finally, Summit Investment Advisors Inc. grew its holdings in Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after purchasing an additional 312 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have commented on MIRM. JMP Securities set a $81.00 price target on Mirum Pharmaceuticals and gave the company a "market outperform" rating in a report on Thursday, August 7th. Evercore ISI increased their price target on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, August 17th. Stifel Nicolaus set a $89.00 price objective on shares of Mirum Pharmaceuticals and gave the stock a "buy" rating in a research note on Monday, August 11th. Finally, HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $74.13.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 40,000 shares of the firm's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the completion of the transaction, the chief executive officer directly owned 138,641 shares of the company's stock, valued at $8,595,742. This trade represents a 22.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jolanda Howe sold 10,000 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total value of $580,000.00. Following the completion of the transaction, the senior vice president directly owned 2,426 shares of the company's stock, valued at approximately $140,708. This trade represents a 80.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 91,041 shares of company stock valued at $5,320,624. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Performance

MIRM stock traded up $2.46 during midday trading on Friday, hitting $71.52. The stock had a trading volume of 1,174,547 shares, compared to its average volume of 737,273. The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of -59.11 and a beta of 0.94. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.86 and a 52 week high of $72.08. The stock has a 50-day simple moving average of $54.81 and a 200 day simple moving average of $48.42. The company has a current ratio of 3.13, a quick ratio of 2.97 and a debt-to-equity ratio of 1.21.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.19. The firm had revenue of $127.79 million during the quarter, compared to analysts' expectations of $107.91 million. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.Mirum Pharmaceuticals's quarterly revenue was up 64.1% compared to the same quarter last year. During the same period last year, the business earned ($0.52) earnings per share. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.